Seeking Alpha

AstraZeneca ramping up virtual R&D model

  • AstraZeneca's (AZN) virtual iMed Oncology division signs an R&D deal with Korea Health Industry to identify early stage projects suitable for funding. The twelve most promising proposals will be chosen for development.
  • The company formed iMed in 2012 as it eliminated 2,200 R&D jobs in an effort to cut costs and increase efficiency. Replacing the large centrally-located bureaucratic structure is a small in-house staff that interacts remotely with collaborators and contractors around the world.
  • iMed's initial success in neuroscience prompted the move into oncology.
Comments (1)
  • Gus999
    , contributor
    Comment (1) | Send Message
    I think is the right time to invest in AZN now that still cheap. Cosindering that next year the pipeline will grow exponentially so will the dividends...
    7 Mar, 04:34 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: